Dermata Therapeutics
DRMA
7 hedge funds and large institutions have $62.4K invested in Dermata Therapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
40% more funds holding
Funds holding: 5 → 7 (+2)
10.91% less ownership
Funds ownership: 13.53% → 2.62% (-11%)
87% less capital invested
Capital invested by funds: $463K → $62.4K (-$401K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$55.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$11.3K |
| 3 |
Barclays
London,
United Kingdom
|
+$7.85K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.14K |
| 5 |
JP Morgan Chase
New York
|
+$2.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$410K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$28.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $39.4K | +$55.5K | +17,000 | New |
|
|
2
Bank of America
Charlotte,
North Carolina
| $8.02K | +$11.3K | +3,453 | +86,325% |
|
|
3
Barclays
London,
United Kingdom
| $5.57K | +$7.85K | +2,402 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $4.64K | +$5.14K | +1,573 | +369% |
|
|
5
UBS Group
Zurich,
Switzerland
| $2.87K | -$28.8K | -8,810 | -88% |
|
|
6
JP Morgan Chase
New York
| $1.61K | +$2.27K | +696 | New |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $234 | – | – | – |
|
|
AC
8
Armistice Capital
New York
| – | -$410K | -81,654 | Closed |
|
DRMA Hedge Fund Activity: Q4 2025 in Review
7 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q4 2025, worth a combined $62.4K — down 87% from $463K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DRMA positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $55.5K. The largest seller was Armistice Capital, exiting entirely with an estimated $410K sold.
- 7 institutional investors held Dermata Therapeutics (DRMA) as of Q4 2025, up from 5 in Q3 2025.
- Funds reported $62.4K of Dermata Therapeutics stock for Q4 2025, down 87% quarter-over-quarter.
- 3 funds opened new Dermata Therapeutics positions in Q4 2025 and 1 closed out, a net change of +2 holders.
- The largest Dermata Therapeutics buyer in Q4 2025 was Clear Street, an estimated $55.5K added.
- The largest Dermata Therapeutics seller in Q4 2025 was Armistice Capital, an estimated $410K sold.
Based on aggregated 13F filings for Q4 2025.